Gross margin dispersion from 38.6% in 2026Q2 to 90.2% in 2025Q1, against a revenue base that has oscillated between roughly $525K and $1.5M quarterly, suggests project mix and cost allocation rather than structural pricing power is driving the reported gross line, making any extrapolated margin assumption unreliable. The 2026Q1 step-up in SG&A to $12.0M, including $8.3M of stock-based compensation, reset the operating cost base roughly three to four times above prior quarters' overhead, so the improvement in operating margin to -9.7% by 2026Q3 reads less as efficiency and more as arithmetic from a larger (still loss-making) revenue print. For underwriting purposes, gross margin is the least informative line here; the operative metric is gross profit dollars versus SG&A, which in 2026Q3 stood at approximately $802K against $3.7M of SG&A — a 4.6x shortfall that defines true earning power far better than any margin percentage.

The apparent narrowing in ROIC (from -18.6% to -10.1%) coincides with a collapse in asset turnover from 0.11 in 2024Q3 to 0.00 in recent quarters, which mathematically compresses the ratio's denominator effect rather than signaling genuine return compounding. Since ROE (-2.7%) sits well above ROIC (-10.1%) in the latest quarter, the gap reflects the absence of debt financing rather than operating leverage — equity is the entire capital base, so returns to shareholders cannot exceed the (negative) returns on invested capital without financial engineering. With retained earnings at -$70.6M and goodwill written down from $11.5M to $371K over roughly four quarters, the historical record shows capital destruction, not compounding; investors should monitor whether the $21.4M of 2026Q3 capex eventually lifts asset turnover above 0.02 before treating any ROIC trend as meaningful.

DSO improvement from 393 days (2024Q4) to 57 days (2026Q3) is the one clear efficiency gain in the dataset, suggesting collections discipline or a shift toward cash-on-delivery terms has tightened receivables; however, with quarterly revenue near $1.4M, a 57-day DSO still implies roughly $220K of receivables, so the absolute working capital swing is modest. DIO of 412 days in the latest quarter against a revenue base this small indicates finished robots or components sitting in inventory for over a year, which is consistent with the project-driven revenue pattern identified in the income statement work and carries obvious obsolescence risk for a technology product. DPO has trended down from 492 days (2024Q4) to 65 days (2026Q3), meaning the company has been paying suppliers faster even as it holds inventory longer — a working capital posture that consumes, rather than generates, cash, and warrants investigation against the $21.4M capex program.

The leverage profile is structurally benign: the company carried D/E of 0.23–0.33 through mid-2024 and has since eliminated that exposure, so refinancing and covenant risk are, on the reported data, negligible — this contrasts sharply with peers like NXRT (D/E 5.18). The extreme interest coverage readings should be discarded analytically rather than interpreted; with essentially no debt service, the binding constraint on Richtech is operating self-sufficiency, not solvency. The relevant forward question is whether the $21.4M expansionary capex in 2026Q3 will be funded from the $302.0M cash position or introduce leverage for the first time in eight quarters; if debt appears in coming filings alongside continued operating losses, the coverage ratios will move from meaningless to material very quickly.

A 38.6x price-to-sales multiple against quarterly revenue of roughly $1.4M is the only earnings-based anchor available, and it presumes a revenue trajectory the last ten quarters do not support (growth swinging from -90.3% to 175.0%). The 0.48x P/B discount to book is the more analytically honest signal: with retained earnings at -$70.6M, the $369M equity base is almost entirely subscribed investor capital, so the market is pricing the operating business at well below zero net of cash — consistent with the negative ROIC profile. Peer set context offers little comfort, as the comparable group spans a bank (BRBS), a biotech (BBOT), and battery/REIT names (MVST, NXRT) with structurally different multiple regimes. Forward P/E and EV/EBITDA are unavailable, which for a loss-making pre-scale manufacturer means the market has no earnings anchor to price against.